Literature DB >> 427686

Persistence of influenza serum antibodies in humans following immunization with a bivalent A/Victoria and A/New Jersey vaccine.

D W Boucher, G Contreras, J Furesz.   

Abstract

The persistence of serum antibodies 1 year after immunization with a bivalent vaccine containing recombinant viruses that were antigenically identical with A/Victoria/3/75 (H3N2) and A/New Jersey/8/76 (Hsw1N1) viruses was measured in 128 persons aged 18 to 65 years. Serum samples were tested with the hemagglutination inhibition assay against the two vaccine antigens and against A/Texas/1/77 (H3N2) and A/USSR/90/77 (H1N1) viruses. Prior to vaccination 56% and 79% of the participants had been found to be seronegative to A/Victoria and A/New Jersey antigens respectively; the geometric mean antibody titres were low (1:5 to 1:11) except in persons aged 51 to 65 years, whose mean titre of antibody to the A/New Jersey antigen was 1:23, and persons aged 26 to 35 years, whose mean titre of antibody to the A/USSR antigen was 1:25. By 3 weeks after vaccination 85% of the seronegative persons had a fourfold or greater rise in titres of antibodies to the viruses in the vaccine, and 70% had a fourfold increase in titre of antibody to the A/Texas antigen. Of the persons aged 26 to 35 years (seronegative and seropositive) 68% had a fourfold or greater increase in titre of antibody to the A/USSR antigen. There was no change in the mean titres of 19 unvaccinated control subjects during the observation period. At 6 and 12 months after vaccination the titres of antibodies to the A/Victoria and A/New Jersey antigens had declined moderately in all age groups from those observed 3 weeks after vaccination. The rate of decline was similar for the various antibodies except that to the A/USSR antigen in persons 26 to 35 years of age, in whom the decline was much slower.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 427686      PMCID: PMC1818961     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  5 in total

1.  A serological recapitulation of human infection with different strains of influenza virus.

Authors:  T FRANCIS; F M DAVENPORT; A V HENNESSY
Journal:  Trans Assoc Am Physicians       Date:  1953

2.  Reactogenicity and immunogenicity of parenteral monovalent influenza A/Victoria/3/75 (H3N2) virus vaccine in healthy adults.

Authors:  E S Caplan; T P Hughes; S O'Donnel; M M Levine; R B Hornick
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

3.  A New Jersey vaccine and A/FM 1/47 epidemics.

Authors:  D E Sarateanu; W Ehrengut
Journal:  Lancet       Date:  1978-01-21       Impact factor: 79.321

4.  Age-related heterologous antibody responses to influenza virus vaccination.

Authors:  G R Noble; H S Kaye; A P Kendal; W R Dowdle
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

5.  Properties of the Hong Kong influenza virus. Antigenic relationship of the Hong Kong virus haemagglutinin to that of other human influenza A viruses.

Authors:  W R Dowdle; M T Coleman; E C Hall; V Knez
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

  5 in total
  1 in total

1.  Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children.

Authors:  Sophia Ng; Vicky J Fang; Dennis K M Ip; Kwok-Hung Chan; Gabriel M Leung; J S Malik Peiris; Benjamin J Cowling
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.